Summary
This retrospective study aimed to evaluate the selection criteria used to determine patient eligibility for MRgFUS (Magnetic Resonance-guided Focused Ultrasound) for the treatment of symptomatic uterine fibroids.
The study included 373 women with symptomatic uterine fibroids who were screened with MRI exams. Patients were initially considered clinically eligible based on standard screening criteria and FDA-based treatment guidelines.
However, the selection criteria were expanded on a case-by-case basis, either to achieve a negative predictive value (NPV) of at least 50% or if the patient declined other treatment approaches such as myomectomy, hysterectomy, or uterine artery embolization.
